India and South Africa recently urged the World Trade Organization to suspend intellectual property protections for COVID-19 vaccines and treatments. The claim is that this would allow developing countries to manufacture “cheap” COVID-19 therapeutics and vaccines, hastening the end to the pandemic—at least, that’s what proponents claim. They’re wrong. Dangerously wrong. Gutting IP protections won’t make COVID-19 medications more readily available but it will set a terrible precedent that will chill future medical innovation.
Recent Posts
- Press Play on American IP: AI Can’t Scratch the Soundtrack to World IP Day
- Other Barks & Bites for Friday, April 25: World IP Day 2025 Celebrates Musicians; Texas A&M to Lead Center for Advanced Aviation Technologies; and Tenth Circuit Affirms Specialty Metals Trade Secret Dismissal
- Judges Seem Frustrated with Judicial Council Arguments in Newman v. Moore Case
- Federal Circuit Reverses PTAB Win for Apple, Finding Board Erred in Its Applicant-Admitted Prior Art Analysis
- IPWatchdog Masters Panelists Urge U.S. Government to Get Organized When It Comes to AI